Intraoperative Electron Beam Radiation Therapy (IOERT) in the Management of Locally Advanced or Recurrent Cervical Cancer

Author(s):  
B.M. Barney ◽  
I.A. Petersen ◽  
M.G. Haddock
Cancer ◽  
1991 ◽  
Vol 67 (6) ◽  
pp. 1504-1508 ◽  
Author(s):  
Christopher G. Willett ◽  
Paul C. Shellito ◽  
Joel E. Tepper ◽  
Roseann Eliseo ◽  
Karen Convery ◽  
...  

1991 ◽  
Vol 9 (5) ◽  
pp. 843-849 ◽  
Author(s):  
C G Willett ◽  
P C Shellito ◽  
J E Tepper ◽  
R Eliseo ◽  
K Convery ◽  
...  

To improve local control and survival in patients with primary locally advanced rectal and rectosigmoid carcinoma, intraoperative electron beam radiation therapy (IORT) has been used with a combination of moderate- to high-dose preoperative radiation therapy and surgical resection. Sixty-five patients underwent resection with the intention of using IORT if areas at high risk for local recurrence were apparent at surgery. For 20 patients undergoing complete resection with IORT, the 5-year actuarial local control and disease-free survival (DFS) was 88% and 53%, respectively. The results for 22 patients with pathologically documented residual carcinoma were less satisfactory with a 5-year actuarial local control and DFS of 60% and 32%, respectively. In this latter group, local control and DFS correlated with the extent of residual disease: patients with only microscopic disease had a 5-year actuarial local control and DFS of 69% and 47%, respectively, whereas for patients with macroscopic disease, these figures were 50% and 17%, respectively. For 18 patients undergoing complete resection without IORT or additional postoperative radiation therapy, the 5-year actuarial local control and DFS was 67% and 53%, respectively. Because local failure will occur in at least 30% of patients undergoing partial resection with or without IORT as well as patients undergoing complete resection of advanced tumors without IORT, additional postoperative radiation therapy should be considered.


Author(s):  
Subir Nag ◽  
Edna Retter ◽  
Rafael Martinez-Monge ◽  
Constance J. Bauer ◽  
Kathryn Klopfenstein ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Otasowie Odiase ◽  
Lindsay Noah-Vermillion ◽  
Brittany A. Simone ◽  
Paul D. Aridgides

In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) were approved in addition to programmed death-ligand 1 (PD-L1) antibodies in 2012. Since then, research showing the effectiveness of targeted therapies in a wide range of solid tumors has prompted studies incorporating their inclusion as part of upfront management as well as refractory or relapsed disease. For treatment of cervical cancer, which arises from known virus-driven oncogenic pathways, the incorporation of targeted therapy is a particularly attractive prospect. The current standard of care for locally advanced cervical cancer includes concurrent platinum-based chemotherapy with radiation therapy (CRT) including external beam radiation therapy (EBRT) and brachytherapy. Building upon encouraging results from trials testing bevacizumab or immunotherapy in recurrent cervical cancer, these agents have begun to be incorporated into upfront CRT strategies for prospective study. This article will review background data establishing efficacy of angiogenesis inhibitors and immunotherapy in the treatment of cervical cancer as well as results of prospective studies combining targeted therapies with standard CRT with the aim of improving outcomes. In addition, the role of immunotherapy and radiation on the tumor microenvironment (TME) will be discussed.


Sign in / Sign up

Export Citation Format

Share Document